Correvio Pharma (NASDAQ:CORV) plans to explore strategic alternatives after yesterday’s negative vote from an FDA advisory committee on its application for Brinavess for the rapid conversion of recent onset atrial fibrillation in adults.
The Company is also taking steps to reduce operating costs outside the core European commercial business.
Shares down 57% premarket on robust volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.